EGFR ELISA 试剂盒

• Frequently cited in scientific publications with 300+ citations
• Validated inhouse for relevant applications
• Extensive validation report for IF provided by one of your peers
• Designed to detect RFP and its variants

• Multiplex ELISA: Testing 5 Targets in 1 Run
• High performance COVID-19 antibody testing
• 99.6% specificity, 95.9% sensitivity

• Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
• Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.617.2 (delta), B.1.1.529 (omicron), B.1.429 (epsilon), B.1.525 (eta), and B.1.617.1 (kappa).
• Frequently used as reference in S-protein ELISAs and neutralization assays.
• Synergizes with other hNAbs: binds a highly conserved epitope, not interefering with the S-protein's ACE2 RBD.

• Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
• Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.429 (epsilon), and B.1.525 (eta).
• Frequently used as reference in S-protein ELISAs and neutralization assays.
• Synergizes with other hNAbs: binds a highly conserved epitope.
• No interference with the ACE2 binding site.

• Dendra2 Antibody (ABIN361314) independently validated for Immunocytochemistry by Neurology Lab (INSERM).
• Publications cite use for Immunoblotting as well as Immunostaining.
• Dendra2 belongs to a new class of photoactivatable fluorescent proteins (PAFPs). PAFPs allow to photolable and track fusion proteins in vivo. Dendra2 Antibody (ABIN361314) can be used for control purposes in this setting.

• Magnetic agarose concanavalin A beads for CUT&RUN and CUT&Tag assays.
• Superior handling compared to magnetic silica concanavalin A beads: easier washes and resuspension.
• Reduced risk for samples to dry out.
• Performance comparable to or better than magnetic silica concanavalin A beads.

• Recombinant SARS-CoV-2 spike protein produced in HEK-293.
• Contains the E484K mutation (present in the novel lineage 501Y.S2 from South Africa) that can affect antibody recognition and enable SARS-CoV-2 immune escape.
• Contains the D614G mutation that renders SARS-CoV-2 infection and replication more efficient.

• Recombinant SARS-CoV-2 spike protein RBD produced in HEK-293.
• Contains the spike protein N501Y mutation (present in the novel lineages B.1.1.7 and 501Y.S2) that has been associated with an increased transmission rate of SARS-CoV-2.

• Recombinant SARS-CoV-2 spike protein RBD produced in HEK-293.
• Contains the spike protein N501Y mutation (present in the novel lineages B.1.1.7 and 501Y.S2) that has been associated with an increased transmission rate of SARS-CoV-2.

• Simultaneous detection of Sp Cas9 binding and cleavage sites in genomic DNA.
• In situ assay leaves cells intact and reduces background.
• Unbiased detection of off-site effects because it is not based on a predictive algorithm.

• Detection of SARS-CoV-2 with variety of different immunoassays, i.e. ELISA, Lateral Flow, as validated by numerous publications (see below).
• Nucleocapsid antibody used for diagnostic Covid19 testing as well as for drug discovery.
• Developed and manufactured in the U.S.

• Has been shown to neutralize SARS-Cov-2 S protein RBD from lineages B.1.1.7, B.1.351, P.1, and B.1.429.
• Suitable as positive control in neutralization antibody screening.
• Humanized chimeric antibody consisting of human IgG1 constant domains and murine variable regions.

• Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.617.
• Contains E154K, L452R, E484Q, D614G, and P681R mutations characteristic for the SARS-CoV-2 kappa variant (B.1.617.1).

• Recombinant trimeric S protein of the SARS-CoV-2 variant of interest B.1.525.
• Contains Q52R, del 69-70, del 144, E484K, F888L, and Q677H mutations characteristic for the SARS-CoV-2 eta variant (B.1.525).

• Recombinant trimeric S protein of the SARS-CoV-2 variant of interest B.1.429.
• Contains S13I, W152C, L452R, and D1183Y mutations characteristic for the SARS-CoV-2 eta variant (B.1.429).

• Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.1.7.
• Contains del 69-70, del 144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H mutations characteristic for the SARS-CoV-2 alpha variant (B.1.1.7).

• Recombinant trimeric S protein of the SARS-CoV-2 variant of concern P.1.
• Contains L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I, and V1176F mutations characteristic for the SARS-CoV-2 gamma variant (P.1).

• Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.617.
• Contains T19R, L452R, T478K, D614G, P681R and D950N mutations characteristic for the SARS-CoV-2 delta variant (B.1.617.2).

• Recombinant trimeric S protein of the SARS-CoV-2 variant of interest B.1.621 mu.
• Contains T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H and D950N mutations characteristic for the SARS-CoV-2 mu variant (B.1.621).

• NLRP3 antibody for reliable recognition of mouse and human NLRP3/NALP3
• This un-conjugated monoclonal antibody has 60 PubMed citations

• 95+ publication references, 1 independent validation
• Frequently used as CUT&RUN IgG negative control and CUT&Tag secondary antibody
• Used in CUT&RUN and CUT&Tag protocols, e.g. Henikoff et al. (2018) PMID 29651053, Kaya-Okur et al. (2019, 2020) PMID 31036827 and PMID 32913232

• Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.1.529 omicron (21K).
• Contains A67V, H69del, V70del, T95I, G142del, V143del, Y144del, Y145D, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, and L981F mutations characteristic for the SARS-CoV-2 omicron variant (B.1.1.529).

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.617.2 delta expressed in insect cells.
• Contains T19R, G142D, E156G, FR157-158 deletion, L452R, T478K, D614G, P681R, and D950N mutations characteristic for the SARS-CoV-2 delta variant (B.1.617.2).
• Intact furin cleavage site 680-SRRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.617.2 delta expressed in insect cells.
• Contains EFR157-158 deletion, T19R, G142D, E156G, FR157-158 deletion, L452R, T478K, D614G, P681R, and D950N mutations characteristic for the SARS-CoV-2 delta variant (B.1.617.2).
• Intact furin cleavage site 680-SRRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern P.1 gamma expressed in insect cells.
• Contains L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, and T1027I mutations characteristic for the SARS-CoV-2 gamma variant (P.1).
• Intact furin cleavage site 680-SPRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern P.1 gamma expressed in insect cells.
• Contains L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F mutations characteristic for the SARS-CoV-2 gamma variant (P.1).
• Intact furin cleavage site 680-SPRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 (M1-P1213) of the SARS-CoV-2 variant of concern B.1.351 expressed in insect cells.
• Contains D80A, K417N, E484K, N501Y, D614G, and A701V mutations characteristic for the SARS-CoV-2 beta variant (B.1.351).
• Intact furin cleavage site 680-SPRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.351 expressed in insect cells.
• Contains L18F, D80A, D215G, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G, and A701V mutations characteristic for the SARS-CoV-2 beta variant (B.1.351).
• Intact furin cleavage site 680-SPRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 (M1-P1213) of the SARS-CoV-2 variant of concern B.1.351 expressed in insect cells.
• Contains L18F, D80A, D215G, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G, and A701V mutations characteristic for the SARS-CoV-2 beta variant (B.1.351).
• Intact furin cleavage site 680-SPRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.1.7 expressed in insect cells.
• Contains HV69-70 deletion, Y145 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H characteristic for the SARS-CoV-2 alpha variant (B.1.1.7).
• Intact furin cleavage site 680-SHRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.1.7 expressed in insect cells.
• Contains HV69-70 deletion, Y144 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H characteristic for the SARS-CoV-2 alpha variant (B.1.1.7).
• Intact furin cleavage site 680-SHRRAR|SV-687.
• C-terminal His-tag.

• Recombinant SARS-CoV-2 wt S protein S1+S2 (M1-P1213) expressed in insect cells.
• Contains D614G mutation.
• Intact furin cleavage site 680-SPRRAR|SV-687.
• C-terminal His-tag.

• High-affinity single-domain antibody
• Recognizes mRFP, mCherry, mScarlet-i, tdTomato, dsRed etc.
• Bead size 50-150 μm

• Monoclonal murine neutralizing antibody (nAb) against SARS-CoV-2 S protein.
• Binds SARS-CoV-2 S proteins of various lineages, including B.1.617.2 (delta) and B.1.1.529 (omicron).
• Ideal for SARS-CoV-2 S-protein ELISAs and neutralization assays.

• Monoclonal murine neutralizing antibody (nAb) against SARS-CoV-2 S protein.
• Binds SARS-CoV-2 S proteins of various lineages, including B.1.617.2 (delta). Does NOT bind the S protein of SARS-CoV-2 B.1.1.529 (omicron).
• Ideal for SARS-CoV-2 S-protein ELISAs and neutralization assays.

• Rabbit beta-Catenin antibody reliably detects beta-Catenin targets in Wnt-signaling using CUT&RUN, ICC, IF, WB, ELISA.
• Well suited to image adherens junctions in IHC/IF.
• Highly specific beta-Catenin detection in WB.

• Rabbit anti-CRBN Antibody reliably detects CRBN in human species.
• Polyclonal, unconjugated antibody for ELISA, WB, IHC.
• Highly specific CRBN detection. See validation images.

• Mouse IL-1 beta ELISA kit for quantitative detection of IL-1 beta.
• Reliable product with validated components.
• ELISA kit cited in more than 40 PubMed References.

• Magnetic agarose Concanavalin A beads for affinity chromatography using a magnetic separator.
• Easy bench-top purification of viruses, virus-like particles (VLP), and cultured cells via reversible binding of glycoproteins, glycolipids, or polysaccharides with terminal mannose or glucose to concanavalin A.

• Polyclonal, unconjugated GFP antibody for reliable detection of GFP and its variants.
• Validated for Fluorescence Microscopy, ELISA, Western Blotting
• High Quality GFP antibody, cited in more than 177 PubMed References.
• Available in 10 µl and 100 µl quantities.

• Reliable Taurine Assay Kit for measurement of free taurine in biological samples.
• Sample taurine concentrations are determined by comparison with a known taurine standard.
• Quick and easy to use.

• Impurity detection in the manufacturing of biological drugs.
• The AccuSignal™ Nuclease ELISA Kit is designed for sensitive and reliable quantification of nucleases in therapeutic products, including DENARASE®, Benzonase®, and Turbonuclease.
• Offers a broad quantification spectrum, maintaining outstanding dilution linearity, instilling trust in the accuracy of results over a wide array of nuclease concentrations.
• Delivers consistent and repeatable outcomes, characterized by minimal intra- and inter-assay variability.
• Tailored antibody specificity allows for application across diverse materials, accommodating various nuclease products from multiple suppliers.
• Components: 96-well strip plate, plate sealer, nuclease standard, biotinylated detection antibody, Streptavidin-HRO (100X), buffers.

• High-affinity anti-GFP single-domain antibody (sdAb) covalently bound to 4 % cross-linked agarose magnetic beads with 50-150 µm diameter.
• The Alpaca sdAb clone 1H1 is specific for GFP and many GFP derivatives. Capacity > 3 μg GFP per μl of packed beads.
• Compatible with physiological buffers, common Lysis and Wash Buffers, and high stringency buffers.

• High-quality FcRn antibody (Clone ADM31) for the detection of FcRn.
• Highly specific for human FcRn, blocks the binding of human serum albumin.
• PBS-only, preservative free
• 15 PubMed references available for this FcRn antibody.

• High-quality FcRn antibody (Clone DVN24) for the detection of FcRn.
• Highly specific for human FcRn, blocks the binding of IgG.
• PBS-only, preservative free
• 2 PubMed references available for this FcRn antibody.

• High-affinity anti-GFP single-domain antibody (sdAb) covalently bound to 4 % cross-linked agarose beads with 50-150 µm diameter.
• The Alpaca sdAb clone 1H1 is specific for GFP and many GFP derivatives. Capacity > 3 μg GFP per μl of packed beads.
• Compatible with physiological buffers, common Lysis and Wash Buffers, and high stringency buffers.

• TrueBlot®: Anti-Rabbit IgG HRP, Mouse Monoclonal eB182
• Manufactured by Rockland Immunochemicals, Inc.
• Rockland Product ID: 18-8816-33

• TrueBlot®: Anti-Rabbit IgG HRP, Mouse Monoclonal eB182
• Manufactured by Rockland Immunochemicals, Inc.
• Rockland Product ID: 18-8816-31

• Anti-ATM Protein Kinase pS1981 (MOUSE) Monoclonal Antibody
• Manufactured by Rockland Immunochemicals, Inc.
• Rockland Product ID: 200-301-400

• High-quality FcRn antibody (Clone ADM31) for the detection of FcRn.
• Highly specific for human FcRn, blocks the binding of human serum albumin.
• contains Glycerol for better storage.

• High-quality FcRn antibody (Clone DVN24) for the detection of FcRn.
• Highly specific for human FcRn, blocks the binding of IgG.
• Contains Glycerol for better storage.

Our GFP Catcher is a product based on the GFP pull-down technique used to isolate GFP fusion proteins from cell lysates. It consists of special magnetic beads (product ABIN7272855) or agarose beads (product ABIN5311508) coated with an antibody against GFP. These beads allow efficient and selective binding to GFP or GFP-fused target proteins.

The application of GFP Catcher is similar to the GFP pull-down method. First, the protein of interest is expressed in the cells with it fused to GFP. Then, the cell lysate is prepared to extract the target proteins. The GFP catcher beads are then added to the cell lysate and bound to these proteins by specifically binding to the GFP or GFP fusion protein.

After the beads with the bound target proteins are isolated, thorough purification is performed to remove components that are not specifically bound. Finally, the target proteins can be separated from the beads and used for further analysis such as immunoblotting or mass spectrometry.

GFP Catcher offers the advantage of quick and easy isolation of GFP fusion proteins. It is a useful tool for protein analysis and allows efficient identification of proteins interacting with GFP fusion protein. GFP Catcher is widely used in cell biology research to study protein-protein interactions and deepen the understanding of cellular processes.

Sequence similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.

Tissue Specificity: Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers. .

Aliquot 0.1 mL per well of the 10000pg/mL, 5000pg/mL, 2500pg/mL, 1250pg/mL, 625pg/mL, 313pg/mL, 156pg/mL human EGFR standard solutions into the precoated 96-well plate. Add 0.1 mL of the sample diluent buffer into the control well (Zero well). Add 0.1 mL of each properly diluted sample of human cell culture supernates, serum, plasma( heparin, EDTA) or human milk to each empty well. See "Sample Dilution Guideline" above for details. It is recommended that each human EGFR standard solution and each sample be measured in duplicate.

• Sample 1: n=16, Mean(ng/ml): 1.37, Standard deviation: 0.053, CV(%): 3.9
• Sample 2: n=16, Mean(ng/ml): 4.68, Standard deviation: 0.211, CV(%): 4.5
• Sample 3: n=16, Mean(ng/ml): 6.21, Standard deviation: 0.329, CV(%): 5.3,
• Sample 1: n=24, Mean(ng/ml): 1.49, Standard deviation: 0.073, CV(%): 4.7
• Sample 2: n=24, Mean(ng/ml): 4.92, Standard deviation: 0.32, CV(%): 6.5
• Sample 3: n=24, Mean(ng/ml): 7.14, Standard deviation: 0.614, CV(%): 8.6

Protein Function: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS- RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.

Background: The epidermal growth factor receptor(EGFR, ErbB-1, HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family(EGF-family) of extracellular protein ligands.1 It is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR(ErbB-1), HER2/c-neu(ErbB-2), Her 3(ErbB-3) and Her 4(ErbB-4). EGFR exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor alpha(TGFalpha). EGFR and its ligands are cell signaling molecules involved in diverse cellular functions, including cell proliferation, differentiation, motility, and survival, and in tissue development. Mutations that lead to EGFR overexpression(known as upregulation) or overactivity have been associated with a number of cancers, including lung cancer and glioblastoma multiforme. In this latter case a more or less specific mutation of EGFR, called EGFRvIII is often observed.

Synonyms: Epidermal growth factor receptor,2.7.10.1,Proto-oncogene c-ErbB-1,Receptor tyrosine-protein kinase erbB-1,EGFR,ERBB, ERBB1, HER1,

Full Gene Name: Epidermal growth factor receptor